key: cord-0945032-huug6nt4
authors: Davoodi, Poorya; Hashemi, Atousa
title: Are the COVID-19’s vaccines efficient on the most dangerous variant of SARS-CoV-2?
date: 2021-09-30
journal: Clin Exp Vaccine Res
DOI: 10.7774/cevr.2021.10.3.301
sha: 4656fe3071989c49e8a5567513b7be38a9d29d5d
doc_id: 945032
cord_uid: huug6nt4

nan

The introduction of COVID-19 vaccine has resulted in a reduction in the number of new cases and deaths in many countries, but the appearance of the Delta variant has raised serious concerns. Since March 20, 2021, around 17% of Delta cases have occurred in vaccinated individuals in Houston, Texas, where a team from Houston Methodist Hospital has been sequencing and recording SARS-CoV-2 variants for nearly every COVID-19 case in the hospital system. Limited studies have been conducted in the Delta species to investigate the efficacy of several vaccinations against SARS-CoV-2, and there is still a lot of conflicting information available [4, 5] .

Sinopharm vaccine is a Chinese product that was given emergency approval by the World Health Organization in May 2021. Based on the assessment the ability of it against Delta variant, researchers have found that Immunogenicity was fairly significant in people under 40 years of age in 98% of cases, but in those over 60 years of age, the success rate was excellent in 93% of cases.

The most famous and well-known vaccine among people is Pfizer that is a novel technology vaccine. The result of a study in Israel shows following the occurrence of the Delta variant, Pfizer infection-prevention efficiency dropped from 94% to 64%. Lopez Bernal et al. [6] evaluated the efficiency of the BNT162b2 and ChAdOx1 nCoV-19 vaccines. In adults with Delta, the efficacy of a single dose of Pfizer (BNT162b2) and AstraZeneca (ChAdOx1 nCoV-19) vaccine was much lower than in Alpha patients. Furthermore, it demonstrates that two Pfizer vaccine doses are more effective than two As-traZeneca vaccine doses. The efficiency of Pfizer was 88% and 36% after two and one dose, respectively. Another study that was published in Nature demonstrated that a single dose of a two-dose vaccine, such as those developed by Pfizer-Bi-oNTech or AstraZeneca, provided "barely" any protection. The results of Pouwels et al. [7] was interesting. They discovered that the efficiency of AstraZeneca is lower than Pfizer-BioNTech, but over time efficiency of Pfizer-BioNTech decreases.

The third vaccine of the list is Moderna. Individuals who were fully vaccinated with Moderna's mRNA-1273 product were substantially less likely than unvaccinated individuals to get moderate or severe outcomes after B.1.617.2 infection, according to several studies. A laboratory evaluation of the Moderna vaccine found that it could protect against the Delta form and other variants tested. In addition, they compared the efficiency of it with Pfizer-BioNTech, and the efficiency for both was approximately 94% [8] .

Johnson & Johnson vaccine is another COVID-19's vaccine that is produced by Janssen Pharmaceutical Companies. The single shot of this vaccine was estimated 91% to 96.2% protection against death and when the Delta variant is dominant, hospitalization is prevented in around 71% of cases [9, 10] .

According to a trial study, the Johnson & Johnson vaccine is roughly 85% effective against the Delta variation, and it also generated higher levels of "neutralizing antibody activity" against the Delta form than the Beta variant, which inhibits the virus from infecting healthy cells [10] .

All in all, the results of different studies show that vaccination still is the best to protect people and stop the spread of COVID-19. Unfortunately, due to several reasons, some countries have used some vaccines that we do not have any information about them, and they have not been approved by the US Food and Drug Administration. Hence, we are not able to understand they are effective on Delta variant or not.

Is computed tomography necessary for the diagnosis of coronavirus disease (COVID-19) in all suspected patients?: a case series

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness

Does endometriosis increase susceptibility to COVID-19 infections?: a case-control study in women of reproductive age

COVID-19: are high rates of B.1.617.2 linked to vaccine hesitancy?

Effectiveness of COVID-19 vaccines against the B.1.617.2 (Delta) variant

Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK

Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study

NY: Cold Spring Harbor Laboratory, me-dRxiv

Comparison of neutralizing antibody titers elicited by mRNA and adenoviral vector vaccine against SARS-CoV-2 variants

Immune response, inflammation, and the clinical spectrum of COVID-19